Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have received a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $46.6667.

A number of analysts have commented on the company. HC Wainwright lowered their price target on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Piper Sandler reaffirmed an “overweight” rating and set a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Wolfe Research assumed coverage on Avalo Therapeutics in a research report on Thursday, April 9th. They set an “outperform” rating and a $48.00 price target for the company. BTIG Research reaffirmed a “buy” rating and set a $58.00 price target on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Finally, Citizens Jmp lowered their price target on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research report on Thursday, May 14th.

Avalo Therapeutics Price Performance

Shares of AVTX stock opened at $17.08 on Thursday. Avalo Therapeutics has a 1-year low of $4.50 and a 1-year high of $24.27. The stock’s fifty day moving average price is $15.57 and its 200 day moving average price is $16.08. The company has a market cap of $897.90 million, a price-to-earnings ratio of -3.13 and a beta of 0.83.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.02. As a group, equities research analysts anticipate that Avalo Therapeutics will post -2.58 earnings per share for the current year.

Insiders Place Their Bets

In other Avalo Therapeutics news, insider Paul Varki sold 75,063 shares of Avalo Therapeutics stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the sale, the insider owned 3,634 shares of the company’s stock, valued at approximately $73,297.78. The trade was a 95.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of Avalo Therapeutics stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the sale, the insider directly owned 3,622 shares of the company’s stock, valued at approximately $65,232.22. This represents a 52.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 112,586 shares of company stock valued at $2,089,651. 4.46% of the stock is owned by company insiders.

Institutional Trading of Avalo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVTX. BIT Capital GmbH acquired a new position in shares of Avalo Therapeutics in the 3rd quarter valued at about $25,000. PFS Partners LLC lifted its holdings in shares of Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after buying an additional 1,000 shares during the period. Boothbay Fund Management LLC acquired a new position in shares of Avalo Therapeutics in the 2nd quarter valued at about $56,000. Dimensional Fund Advisors LP acquired a new position in shares of Avalo Therapeutics in the 3rd quarter valued at about $143,000. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Avalo Therapeutics in the 1st quarter valued at about $174,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.